{"id":9012,"date":"2024-09-16T16:01:12","date_gmt":"2024-09-16T09:01:12","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=9012"},"modified":"2024-09-16T16:01:12","modified_gmt":"2024-09-16T09:01:12","slug":"akesos-ivonescimab-plus-chemo-in-first-line-triple-negative-breast-cancer-showed-promising-preliminary-efficacy-and-good-safety-at-esmo-2024","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=9012","title":{"rendered":"Akeso’s Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024"},"content":{"rendered":"

HONG KONG<\/span><\/span>, Sept. 16, 2024<\/span><\/span> \/PRNewswire\/ — At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK<\/span>) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The preliminary data, with only a 10-month median follow-up, revealed that the ivonescimab combination regimen demonstrated excellent efficacy and a favorable safety profile in 1L TNBC. Professor Wang Xiaojia from Zhejiang Provincial Cancer Hospital, a co-primary investigator of the study, presented the findings orally at the conference.<\/p>\n

As of May 31, 2024<\/span>, a total of 30 patients with locally advanced unresectable or metastatic TNBC were enrolled. 80% of patients had a PD-L1 combined positive score (CPS) <10, and 60% of patients had previously received taxane-based neoadjuvant or adjuvant therapy (a proportion higher than that observed in similar studies involving targeted drugs).<\/p>\n

Although the follow-up period is relatively short and the data are not yet mature, the study still demonstrates that the ivonescimab combination regimen demonstrates excellent progression-free survival (PFS) benefits for TNBC patients, with safety consistent with previous ivonescimab-related studies.<\/p>\n

Ivonescimab combination regimen demonstrated high efficacy in tumor response and disease control, with an objective response rate (ORR) of 72.4% and a disease control rate (DCR) of 100%, including a complete response (CR) rate of 6.9%. As of the latest update, five additional patients have achieved partial response (PR) (Among them, four newly\u00a0evaluable patients all achieved a PR, and one patient who previouly had stable disease also achieved a PR ), leading to an adjusted ORR of approximately 78.8% and DCR of 100%. Ivonescimab combination regimen showed a promising trend towards improved long-term survival benefits, with a median progression-free survival (PFS) of 9.3 months (6.24 months -NE), and a 6-month PFS rate of 73.3%. In the PD-L1 CPS\u226510 population, the\u00a0ORR was 83.3%, and the median PFS was not yet reached. In the PD-L1 CPS <1 population, the\u00a0ORR was 86.7%, with a median PFS of 9.3 months (5.26 months-NE). As of the latest update, two additional patients in the PD-L1 CPS <1 group have achieved PR, resulting in an adjusted\u00a0ORR of 88.2%. In the PD-L1 CPS <10 population, the\u00a0ORR was 69.6%, with a median PFS of 9.3 months (5.55 months-NE). As of the latest update, five additional patients in this group have achieved PR, leading to an adjusted\u00a0ORR of approximately 77.8%. Ivonescimab combined with chemotherapy as a first-line treatment for TNBC exhibited an acceptable safety profile. The most common treatment-related adverse events (TRAEs) were predominantly grade 1-2 and manageable, consistent with previous studies. There were no TRAEs that led to permanent treatment discontinuation or death. <\/p>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

HONG KONG<\/span><\/span>, Sept. 16, 2024<\/span><\/span> \/PRNewswire\/ — At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK<\/span>) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The preliminary data, with only a 10-month median follow-up, revealed that the ivonescimab combination regimen demonstrated excellent efficacy and a favorable safety profile in 1L TNBC. Professor Wang Xiaojia from Zhejiang Provincial Cancer Hospital, a co-primary investigator of the study, presented the findings orally at the conference.<\/p>\n

As of May 31, 2024<\/span>, a total of 30 patients with locally advanced unresectable or metastatic TNBC were enrolled. 80% of patients had a PD-L1 combined positive score (CPS) <10, and 60% of patients had previously received taxane-based neoadjuvant or adjuvant therapy (a proportion higher than that observed in similar studies involving targeted drugs).<\/p>\n

Although the follow-up period is relatively short and the data are not yet mature, the study still demonstrates that the ivonescimab combination regimen demonstrates excellent progression-free survival (PFS) benefits for TNBC patients, with safety consistent with previous ivonescimab-related studies.<\/p>\n

Ivonescimab combination regimen demonstrated high efficacy in tumor response and disease control, with an objective response rate (ORR) of 72.4% and a disease control rate (DCR) of 100%, including a complete response (CR) rate of 6.9%. As of the latest update, five additional patients have achieved partial response (PR) (Among them, four newly\u00a0evaluable patients all achieved a PR, and one patient who previouly had stable disease also achieved a PR ), leading to an adjusted ORR of approximately 78.8% and DCR of 100%. Ivonescimab combination regimen showed a promising trend towards improved long-term survival benefits, with a median progression-free survival (PFS) of 9.3 months (6.24 months -NE), and a 6-month PFS rate of 73.3%. In the PD-L1 CPS\u226510 population, the\u00a0ORR was 83.3%, and the median PFS was not yet reached. In the PD-L1 CPS <1 population, the\u00a0ORR was 86.7%, with a median PFS of 9.3 months (5.26 months-NE). As of the latest update, two additional patients in the PD-L1 CPS <1 group have achieved PR, resulting in an adjusted\u00a0ORR of 88.2%. In the PD-L1 CPS <10 population, the\u00a0ORR was 69.6%, with a median PFS of 9.3 months (5.55 months-NE). As of the latest update, five additional patients in this group have achieved PR, leading to an adjusted\u00a0ORR of approximately 77.8%. Ivonescimab combined with chemotherapy as a first-line treatment for TNBC exhibited an acceptable safety profile. The most common treatment-related adverse events (TRAEs) were predominantly grade 1-2 and manageable, consistent with previous studies. There were no TRAEs that led to permanent treatment discontinuation or death. <\/p>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-9012","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/9012","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9012"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/9012\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9012"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9012"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9012"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}